Evidence-anchored guide — from foundational definitions to phenotype-specific therapy.
Before picking a therapy, get the vocabulary right. These distinctions — cardiomyopathy vs. heart failure, structural disease vs. clinical syndrome — drive every downstream decision.
A heterogeneous group of diseases of the myocardium associated with mechanical and/or electrical dysfunction, usually exhibiting inappropriate ventricular hypertrophy or dilatation, and due to a variety of causes that are frequently genetic (AHA 2006; updated ESC 2023).
Cardiomyopathy is a structural / functional diagnosis of the muscle itself. It may be confined to the heart (primary) or part of a systemic disorder (secondary).
A patient can have cardiomyopathy without heart failure (e.g., asymptomatic HCM carrier), and a patient can have heart failure without classical cardiomyopathy (e.g., severe MR from a flail leaflet, constrictive pericarditis).
A complex clinical syndrome resulting from any structural or functional impairment of ventricular filling or ejection of blood (2022 AHA/ACC/HFSA).
Heart failure is defined by symptoms and signs (dyspnea, fatigue, fluid retention, elevated JVP, pulmonary crackles) plus objective evidence of cardiac dysfunction at rest. Biomarkers (BNP/NT-proBNP) and imaging confirm.
"Heart failure" always requires further qualification: EF category (HFrEF/HFmrEF/HFpEF/HFimpEF), stage (A-D), NYHA class (I-IV), and underlying etiology (ischemic, hypertensive, valvular, cardiomyopathic, etc.).
The 2023 ESC cardiomyopathy guideline moved away from the older "primary/secondary/mixed" model toward a phenotype-first approach. You identify the morphologic phenotype, then trace the etiology.
| Phenotype | Morphology | Classic Etiologies | Key Clue |
|---|---|---|---|
| HCM Hypertrophic | LV wall ≥15 mm (≥13 mm if family hx), non-dilated | Sarcomeric mutations (MYH7, MYBPC3), Fabry, amyloid, syndromic | Dynamic LVOT gradient, family hx SCD |
| DCM Dilated | LV dilation + systolic dysfunction (LVEDD >112% predicted, EF <50%) not explained by loading conditions | Genetic (TTN, LMNA), ischemic, viral myocarditis, alcohol, chemotherapy (anthracycline, trastuzumab), peripartum, tachycardia-mediated | Global hypokinesis, family hx DCM |
| NDLVC Non-dilated LV cardiomyopathy | Non-dilated hypokinetic LV or scar/fibrosis without regional wall motion abnormality | Genetic (DSP, FLNC, LMNA, RBM20), myocarditis residua, sarcoid | New category added in 2023 ESC — LGE on CMR with preserved size |
| ARVC Arrhythmogenic RV | RV free wall fibrofatty replacement, dilation, aneurysms | Desmosomal mutations (PKP2, DSP, DSG2) | T-wave inversion V1–V3, epsilon wave, exercise-induced VT |
| RCM Restrictive | Stiff ventricle with impaired filling, preserved EF, non-dilated | Amyloid (AL, ATTR), sarcoid, hemochromatosis, radiation, endomyocardial fibrosis, Löffler's | Biatrial enlargement, elevated JVP with prominent y-descent |
The 2023 ESC shift emphasizes that HCM is not always sarcomeric (30% is genetic, 10% is infiltrative like Fabry or amyloid) and that identifying the true etiology changes management — tafamidis for ATTR, enzyme replacement for Fabry, myectomy or mavacamten for obstructive sarcomeric HCM.
HFpEF is a clinical syndrome characterized by signs and symptoms of HF with LVEF ≥50%. Many HFpEF patients have an underlying cardiomyopathic process — most commonly hypertensive heart disease with concentric remodeling, but also infiltrative (ATTR-CA accounts for up to 13% of HFpEF in older adults), HCM with preserved EF, or restrictive processes.
So "HFpEF" is a bucket that mixes heterogeneous etiologies. Identifying which flavor the patient has changes therapy dramatically.
Three orthogonal axes: ejection fraction, stage of disease (A–D), and functional capacity (NYHA). Modern guidelines layer a fourth — "HFimpEF" — for patients whose EF recovers.
The universal definition unified LVEF categories across societies. Drug evidence maps cleanly onto these cutoffs — this is why the categories matter clinically.
| Category | LVEF | Defining Therapy Evidence | Notes |
|---|---|---|---|
| HFrEF Reduced | ≤40% | All 4 pillars: ARNI/ACEi/ARB + BB + MRA + SGLT2i | Largest trial base. Targets neurohormonal activation. |
| HFmrEF Mildly reduced | 41–49% | SGLT2i (Class 2a), ARNI/ACEi/ARB/BB/MRA (Class 2b) | Renamed from "mid-range" in 2021 UDHF. Many behave like HFrEF. |
| HFpEF Preserved | ≥50% | SGLT2i (Class 1, 2022 update), MRA / ARNI / ARB (Class 2b) | DELIVER + EMPEROR-Preserved → SGLT2i works across full EF range. |
| HFimpEF Improved | Baseline ≤40%, now >40% with ≥10-pt rise | Continue all HFrEF therapy | TRED-HF (2019): withdrawing GDMT → 40% relapse. Never de-escalate. |
Patients feel well, EF looks normal, and clinicians stop GDMT "because they're better." TRED-HF showed 44% relapse within 6 months of withdrawal. Recovery is remission, not cure.
Stages describe the disease — they never regress. Once Stage C, always Stage C, even with EF recovery.
| Stage | Meaning | Example |
|---|---|---|
| A At risk | Risk factors (HTN, DM, obesity, CAD, cardiotoxins, family hx) — no disease, no symptoms | 60-yo with DM + HTN, normal echo |
| B Pre-HF | Structural disease (LVH, reduced EF, valve disease, prior MI) — no symptoms | Asymptomatic EF 30% after silent MI |
| C Symptomatic HF | Structural disease + current/prior HF symptoms | EF 25%, dyspnea on exertion |
| D Advanced | Refractory HF despite GDMT — needs advanced therapies or hospice | INTERMACS 3, recurrent admissions |
NYHA describes current symptoms — it does move (unlike stages). Used for drug initiation thresholds and to track response.
| Class | Symptoms |
|---|---|
| I | No limitation of physical activity |
| II | Slight limitation — ordinary activity causes dyspnea/fatigue |
| III | Marked limitation — less than ordinary activity causes symptoms |
| IV | Symptoms at rest or minimal exertion |
A patient with EF 22%, s/p CABG, no current symptoms on GDMT → Stage C (ever had symptoms), NYHA I (currently well).
Originally called "HF with mid-range EF" in the 2016 ESC guideline, renamed "HF with mildly reduced EF" in the 2021 Universal Definition of HF. The rename was deliberate — "mid-range" implied stability, but the data say these patients are dynamic and often behave like HFrEF.
| Therapy | Class of Rec |
|---|---|
| SGLT2i (dapa/empa) | Class 2a — DELIVER, EMPEROR-Preserved included EF >40% |
| ARNI / ACEi / ARB | Class 2b — PARAGON-HF subgroup signal |
| Beta-blocker | Class 2b — extrapolation + some subgroup data |
| MRA (spiro/epler/finerenone) | Class 2b — TOPCAT Americas; FINEARTS-HF positive in EF ≥40% |
| Diuretics | Class 1 — congestion, as always |
Treat HFmrEF as HFrEF-lite: initiate the 4 pillars at the earliest signal that the phenotype is moving toward reduced EF, especially in patients with prior HFrEF, ischemic etiology, or active remodeling. SGLT2i is the only pillar with true Class 2a evidence here; the rest rely on mechanistic extrapolation and post-hoc signals — but the risk–benefit favors use.
Roughly half of US HF patients have preserved EF. The balance shifts toward HFpEF with age, female sex, and obesity — and HFpEF has overtaken HFrEF as the dominant phenotype in the outpatient HF clinic.
Every suspected HF encounter: history + exam → natriuretic peptides + ECG + echo. If EF is preserved, you're not done — HFpEF diagnosis is probabilistic and demands active hunting for mimics.
| Setting | BNP | NT-proBNP |
|---|---|---|
| Acute dyspnea — rule out | <100 pg/mL | <300 pg/mL |
| Acute — rule in | >500 | >450 (<50y), >900 (50–75y), >1800 (>75y) |
| Ambulatory — rule out | <35 | <125 |
False low: obesity (BMI >35), flash pulmonary edema, HFpEF early. False high: AF, CKD (especially NT-proBNP), advanced age, sepsis, PE. ARNI effect: sacubitril/valsartan raises BNP (blocks neprilysin breakdown) but lowers NT-proBNP — trend NT-proBNP once on ARNI.
| Finding | Suggests |
|---|---|
| Eccentric LV dilation, thin walls | DCM (ischemic, idiopathic, viral, toxic) |
| Concentric LVH, normal/small cavity | Hypertensive HD, HCM, infiltrative |
| Septal:posterior wall >1.3, LVOT obstruction | HCM (asymmetric) |
| Biatrial enlargement, granular sparkling myocardium, low tissue Doppler velocities, apical sparing on strain | Cardiac amyloidosis (ATTR or AL) |
| Restrictive filling, respirophasic septal bounce | Constrictive pericarditis (mimic!) |
| RV dilation, akinesis, aneurysms | ARVC, PE, PH |
| Global hypokinesis with regional LAD territory | Takotsubo (apical ballooning) |
When EF is preserved, the echo shows diastolic dysfunction, and the patient has dyspnea — is this HFpEF or something else? H2FPEF gives a probability estimate (range 0–9). Check the boxes that apply:
The European HFA-PEFF algorithm uses 4 domains (functional, morphologic, biomarker, invasive) each scored 0–2. Total ≥5 confirms HFpEF; 2–4 requires stress testing. Both scores converge when clinical gestalt, obesity, and AF are present.
Tap any card for diagnostic criteria, red flags, and phenotype-specific therapy. The cardiomyopathy landscape has been transformed by disease-modifying drugs — tafamidis for ATTR, mavacamten for obstructive HCM.
Hover for a preview — click to lock the detail panel until you pick another.
| Mimic | Clue | Confirm | Treatment changes how? |
|---|---|---|---|
| Cardiac amyloidosis (ATTR) | Male >65, bilateral carpal tunnel, low-voltage ECG despite LVH, apical sparing on strain | Technetium-PYP scan + monoclonal screen | Tafamidis, stop diltiazem/verapamil, avoid ACEi in advanced disease (hypotension) |
| Constrictive pericarditis | Prior radiation/cardiac surgery/TB, Kussmaul sign, pericardial knock | CMR (pericardial thickening >4 mm), invasive hemodynamics | Pericardiectomy (curative) |
| High-output HF | Warm extremities, wide pulse pressure, AV fistula / thyrotoxicosis / anemia / obesity / cirrhosis | Address underlying cause | Diuresis worsens — fix the cause |
| Severe valvular disease | Murmur (or silent AS in elderly) | Echo | TAVR/SAVR for AS; MV repair for primary MR |
| Primary pulmonary HTN | Isolated RV dysfunction, normal LA size | RHC (PCWP normal, PVR elevated) | PAH-specific therapy — wrong to diurese aggressively |
Modern HFrEF care starts all four pillars rapidly — often within the first hospitalization — titrating to target or maximum tolerated dose. The sequence matters less than the totality.
The 2022 update moved away from "stepwise over months" toward simultaneous, low-dose initiation of all 4 pillars with rapid titration. STRONG-HF (2022) confirmed that high-intensity in-hospital initiation reduced 180-day death/readmission (15% vs 23%). Start low, start all four, titrate fast.
| Drug | Trial | Outcome |
|---|---|---|
| Empagliflozin | EMPEROR-Preserved (2021) | 21% ↓ CV death/HFH |
| Dapagliflozin | DELIVER (2022) | 18% ↓ CV death/worsening HF |
| Finerenone | FINEARTS-HF (2024) | 16% ↓ CV death/worsening HF |
| Spironolactone | TOPCAT (2014) | Neutral overall; benefit in Americas cohort |
| Sacubitril-valsartan | PARAGON-HF (2019) | Borderline miss; signal in women, EF 45–57% |
| Semaglutide (if obese) | STEP-HFpEF (2023) | ↓ symptoms, weight, NT-proBNP, CRP |
Diuretics treat congestion but do not change mortality. The SGLT2 class is now the backbone of HFpEF therapy — recommended across the entire EF spectrum.
| Device | Primary prevention indication |
|---|---|
| ICD | EF ≤35%, NYHA II–III, ≥40 d post-MI / 90 d post-revasc, on optimal GDMT, ≥1-yr meaningful survival expected |
| CRT-D | EF ≤35% + LBBB + QRS ≥150 ms + NYHA II–IV on GDMT (Class 1). LBBB 120–149 ms or non-LBBB ≥150 ms = Class 2a. |
| CRT response | Best: female, LBBB, QRS >150, non-ischemic. ~30% non-responders overall. |
Bridge during 40/90-day GDMT optimization after MI or new DCM. VEST trial (2018) did not show clear mortality benefit — use selectively.
| Condition | Drug | Mechanism | Key trial |
|---|---|---|---|
| ATTR-CM (wild-type & variant) | Tafamidis | TTR tetramer stabilizer | ATTR-ACT: 30% ↓ all-cause mortality |
| ATTR-CM | Acoramidis | Near-complete TTR stabilization | ATTRibute-CM (2023): 25% ↓ composite |
| ATTR (variant) | Patisiran / Vutrisiran / Inotersen | TTR silencing (RNAi / ASO) | APOLLO-B, HELIOS-B |
| Obstructive HCM | Mavacamten | Cardiac myosin inhibitor | EXPLORER-HCM: ↓ LVOT gradient, ↓ need for myectomy |
| AL amyloidosis | Dara-CyBorD | Plasma cell–directed chemo + daratumumab | ANDROMEDA: 78% hematologic response |
| Cardiac sarcoidosis | Prednisone ± methotrexate / infliximab | Granuloma suppression | Observational; no RCT |
| Iron deficiency in HFrEF | IV ferric carboxymaltose / derisomaltose | Replete myocardial iron | AFFIRM-AHF, IRONMAN: ↓ HFH |
When GDMT is maximal and the patient remains congested, hypotensive, or functionally limited: time to escalate.
| Therapy | Best for | Trade-off |
|---|---|---|
| Continuous inotropes (milrinone, dobutamine) | Bridge-to-transplant/LVAD or palliation | ↑ arrhythmia, ↑ mortality with long-term use |
| LVAD (HeartMate 3) | INTERMACS 2–4; bridge or destination | Stroke, bleeding (less with HM3), pump thrombosis |
| Heart transplant | INTERMACS 3–4, age <70, no significant comorbidities | Lifelong immunosuppression, ~50% alive at 13 y |
| Palliative care | Any stage D, high symptom burden, poor prognosis | Not "giving up" — concurrent with GDMT |
A catalog of the misunderstandings, missed diagnoses, and wrong moves that show up repeatedly in real practice and on boards. Click a domain to load its pitfalls.
| Pitfall | Why it matters | Do instead |
|---|---|---|
| Trending BNP in a patient on ARNI | Sacubitril inhibits neprilysin, which normally degrades BNP → BNP rises on ARNI despite clinical improvement. NT-proBNP is neprilysin-independent. | Use NT-proBNP to trend response once ARNI is started (or known). |
| Ignoring renal effects on NT-proBNP | NT-proBNP is cleared renally. eGFR <60 makes it falsely high. BNP less affected but still rises in CKD. | Use age-adjusted NT-proBNP cutoffs in acute setting; interpret trends, not absolute values, in CKD. |
| Calling HF "ruled out" with a low BNP in obesity | BMI >35 suppresses BNP/NT-proBNP by ~40–50% via adipose clearance and reduced secretion. Obese HFpEF patients can have BNP <100. | Normal BNP in an obese patient does not rule out HFpEF — use echo + H2FPEF. |
| False high BNP/NT-proBNP from non-HF causes | AF, sepsis, pulmonary embolism, advanced age, ACS, cardiomyopathies of any cause all raise NP independently of HF status. | Interpret BNP in full clinical context; BNP is a marker of myocyte stretch, not exclusively HF. |
| Flash pulmonary edema with normal BNP | BNP takes hours to rise — acute mitral regurgitation or diastolic flash can present before BNP climbs. | Trust the clinical picture and imaging; do not exclude HF on one early BNP. |
| Pitfall | Why harmful | Correct approach |
|---|---|---|
| Diltiazem or verapamil in HFrEF | Negative inotropy → worsens EF and precipitates decompensation (MDPIT). | Non-DHP CCBs are contraindicated in HFrEF. Use amlodipine if CCB needed (PRAISE neutral for mortality, safe for HTN/angina). |
| Non-DHP CCBs in ATTR amyloidosis | Diltiazem binds amyloid fibrils → worse AV block, shock. | Avoid in any patient with confirmed or suspected amyloid. |
| Digoxin in ATTR or in renal disease | Digoxin binds amyloid; narrow therapeutic index; renal clearance. High toxicity risk. | Avoid in amyloid; dose by renal function and trough level if used elsewhere (0.5–0.9 ng/mL). |
| Thiazolidinediones (pioglitazone, rosiglitazone) in HF | Fluid retention via ENaC; ~2× risk of HF hospitalization. | Avoid in NYHA III–IV; caution in II. Use SGLT2i or GLP-1 RA instead. |
| Saxagliptin & alogliptin in HF | SAVOR-TIMI 53 and EXAMINE: ↑ HF hospitalization signal. | Prefer other DPP-4 inhibitors (linagliptin, sitagliptin) or switch class to SGLT2i/GLP-1 RA. |
| Dronedarone in HFrEF or recently decompensated HF | ANDROMEDA: 2× mortality in NYHA III–IV. PALLAS: harmful in permanent AF. | Contraindicated in any HFrEF. Use amiodarone (safe in HF) for rhythm control. |
| NSAIDs in HF | Sodium retention, ↓ renal perfusion, ↓ diuretic efficacy, ↑ HF hospitalization. | Avoid; use acetaminophen or topical agents. If absolutely needed, limit duration and monitor weight/Cr. |
| Ivabradine in AF | If-channel inhibitor only works in sinus rhythm. In AF it doesn't slow rate and may worsen outcomes. | Only prescribe for sinus HR ≥70 on max-tolerated BB with NYHA II–IV, EF ≤35%. |
| Vasodilators (nitrates, DHP-CCBs) in obstructive HCM | ↓ preload/afterload → ↑ LVOT gradient → syncope, sudden death. | Use BB or non-DHP CCB; avoid diuretics during exacerbations unless truly volume overloaded. |
| Beta-blocker in acute decompensated HF (withdrawing what the patient is on) | B-CONVINCED and others: continuing (or dose-reducing, not stopping) BB is associated with better post-discharge outcomes than full withdrawal. | If already on a BB, continue at reduced dose unless cardiogenic shock. Initiate BB only once euvolemic. |
| Pitfall | Why harmful | Correct approach |
|---|---|---|
| Stopping GDMT after EF recovers ("HFimpEF") | TRED-HF (2019): 44% relapse within 6 months of withdrawal; 1/3 had symptomatic HF. | Continue the 4 pillars indefinitely. Recovery is remission, not cure. |
| Under-dosing ARNI / ACEi / BB (staying at starter doses forever) | Most mortality benefit is dose-dependent (CIBIS-II, MOCHA). ~40% of real-world patients never reach target dose. | Titrate every 2 weeks to target or maximum tolerated. Low BP/HR is often tolerable if asymptomatic. |
| Avoiding MRA due to K+/Cr fears | RALES halved mortality; real-world K+ ≥5.5 occurs in <10% with proper monitoring. Fear of hyperkalemia under-uses a life-saving drug. | Start spironolactone 12.5–25 mg if K+ ≤5.0 and eGFR ≥30; recheck at 2–4 weeks. Use patiromer / SZC if K+ limits titration. |
| Holding ACEi/ARB/ARNI for modest creatinine rise | A 20–30% rise in Cr after initiation is expected (efferent arteriole dilation) and does not mean failure. | Tolerate Cr up to 30% rise with stable K+; investigate only if rise exceeds 30% or K+ >5.5. |
| Sequential, months-long titration of pillars | STRONG-HF (2022): rapid (within 6 weeks) initiation of all 4 pillars → 34% ↓ death/readmission vs. usual care. | Initiate all 4 in hospital at low doses, then rapid outpatient up-titration. Don't wait for "perfect" dose of one before starting the next. |
| Skipping ivabradine/vericiguat because the 4 pillars "should suffice" | Residual risk persists despite the 4 pillars; add-ons (ivabradine, vericiguat, IV iron, hydralazine/ISDN) are evidence-based for specific subgroups. | Reassess every visit — there's almost always another evidence-based addition. |
| Pitfall | Red flag | Why it matters |
|---|---|---|
| Missing cardiac amyloidosis in HFpEF | Male >65, bilateral CTS, low-voltage LVH on ECG, apical sparing on strain | Up to 13% of HFpEF in this demographic is ATTR-CM. Tafamidis changes mortality. Missing the diagnosis = missing disease-modifying therapy. |
| Calling ATTR without ruling out AL | AL has different treatment (chemotherapy), much worse prognosis | Always check serum free light chains + SPEP/UPEP before tafamidis. PYP positive + monoclonal protein → biopsy required. |
| Misreading restrictive CMP as constrictive pericarditis (or vice versa) | Constriction: septal bounce, preserved e′ velocities, thick pericardium. RCM: infiltrated myocardium, low e′. | Constriction is surgically curable. Missed diagnosis costs the patient a cure. |
| Diuresing high-output HF | Warm extremities, wide pulse pressure, AV fistula / thyrotoxicosis / severe anemia / cirrhosis / obesity | Diuresis makes high-output HF worse. Fix the underlying cause (close fistula, treat thyroid, transfuse). |
| Treating tachycardia-mediated CMP as "idiopathic DCM" | Persistent AF with RVR or incessant SVT in a patient with new HF and no CAD | Rate/rhythm control can normalize EF within weeks. CASTLE-AF: AF ablation superior to drug therapy in HFrEF + AF. |
| Missing iron deficiency in HFrEF | Ferritin <100 or (ferritin 100–300 AND TSAT <20%), with or without anemia | Affects ~50% of HFrEF patients. IV iron (AFFIRM-AHF, IRONMAN) reduces HF hospitalizations. Oral iron (IRONOUT-HF) does NOT work. |
| Ignoring sleep apnea | Witnessed apneas, daytime fatigue, refractory HTN or AF | OSA worsens HF outcomes. CPAP improves EF in OSA. Central sleep apnea (Cheyne-Stokes) common in HFrEF — adaptive servo-ventilation harmful in EF ≤45% (SERVE-HF). |
| Calling a drop in EF "progression" without checking adherence/triggers | New AF, thyroid dysfunction, alcohol, cocaine, NSAIDs, chemo, pregnancy, ICI myocarditis | Always hunt for a reversible driver before escalating to advanced therapies. |
| Pitfall | Explanation | Fix |
|---|---|---|
| Diuretic resistance unrecognized | GFR drop, bowel edema → ↓ diuretic absorption; nephron remodeling ↑ distal Na reabsorption (braking phenomenon). | Double the IV loop dose (DOSE trial: high-dose strategy = more diuresis). Add thiazide (metolazone or chlorothiazide) for sequential nephron blockade. Monitor Na, K, Mg, Cr closely. |
| Using IV loop dosing equal to PO home dose | Oral bioavailability of furosemide is 50% (and variable). Equal-dose IV = effective doubling. | Start at ≥2× home oral dose when switching to IV; consider torsemide/bumex if erratic furosemide absorption. |
| Treating HFpEF exacerbation like HFrEF (aggressive diuresis + vasodilation) | HFpEF patients are more preload-sensitive; aggressive reduction → hypotension, AKI. | Gentler diuresis; avoid nitrates if hypotensive; hunt for precipitant (AF, HTN crisis, dietary indiscretion). |
| Diuresing a patient in cardiogenic shock | Congestion persists because of low cardiac output, not just volume overload. Diuresing a cold-wet patient without inotropy worsens perfusion. | Inotrope or mechanical support first if end-organ hypoperfusion (low MAP, high lactate, cold extremities, rising Cr). |
| Over-reliance on daily weights alone | Weight changes lag congestion by days; patients with advanced HF can be congested at "dry weight." | Use JVP, orthopnea, bendopnea, BNP trend and weight. Consider CardioMEMS PA pressure monitoring (GUIDE-HF) in selected patients. |
| Pitfall | Consequence | Correct |
|---|---|---|
| Placing a primary-prevention ICD too early post-MI / post-revasc | DINAMIT & IRIS: ICD within 40 d of MI does not reduce mortality (non-SCD balances out). | Wait 40 days after MI, 90 days after revascularization, and re-evaluate EF on GDMT first. Bridge with LifeVest if very high risk. |
| Implanting CRT in narrow QRS | EchoCRT (QRS <130 ms): CRT increased mortality despite echo dyssynchrony. | QRS ≥150 ms with LBBB is ideal; QRS 120–149 or non-LBBB ≥150 is Class 2a; <120 = no. |
| AF ablation in advanced structural disease without realistic expectations | Success rates drop with LA enlargement; some patients still need rate control. | CASTLE-AF showed benefit in HFrEF + AF; select fit patients; consider rate control (+BB/digoxin) if high-risk. |
| LVAD / transplant referral too late | INTERMACS 1–2 (cardiogenic shock / inotrope-dependent) patients have worse post-LVAD outcomes than 3–4. | Refer for advanced therapy evaluation when any "I-NEED-HELP" triggers present (IV inotropes, NYHA IIIb–IV despite GDMT, EF <25%, End-organ dysfunction, etc.). |
| Pitfall | Why it matters | Get it right |
|---|---|---|
| Confusing Stage with NYHA class | Stages (A–D) describe disease and don't regress; NYHA describes current symptoms and does. A Stage C patient can be NYHA I. | Document both axes on every note. EF category is a third axis. |
| Equating "EF 55%" with "normal heart" | EF is load-dependent and insensitive to early disease. Strain imaging picks up subclinical dysfunction (chemo surveillance, amyloid apical sparing). | Request GLS on echo; EF >50% with GLS < -16% is abnormal. |
| Using "diastolic HF" interchangeably with HFpEF | HFpEF is a syndrome, not purely a diastolic problem — it also involves impaired atrial compliance, chronotropic incompetence, and peripheral factors. | Use "HFpEF" and hunt for the dominant pathophysiology (obesity, AF, amyloid, HCM, hypertensive remodeling). |
| Treating every EF <50% as HFrEF | HFmrEF (41–49%) has a different (lighter) evidence base and frequently transitions in either direction. | Document the category precisely and reassess at 3 months. |
1. Watching a falsely-rising BNP on ARNI and panicking. 2. Stopping GDMT when EF recovers. 3. Missing ATTR amyloidosis in an elderly man with "stiff-heart HFpEF" — because once you stop thinking about it, you'll never find it.
Four decades of evidence, compressed. Every modern HF guideline recommendation traces back to one of these studies. Hazard ratios are for the primary endpoint vs. placebo or active comparator.
Hover any bar or list row for a preview. Click to pin the detail panel until you pick another.
Lower HR = more benefit vs. comparator. Effect size varies by population (HFrEF vs HFpEF) and comparator drug.
Ten years ago, HFpEF had no disease-modifying therapy and HFrEF used a 3-drug regimen. The landscape has been rebuilt — here's the timeline, and the exact changes to each recommendation.
Hover any data point for the landmark trial and guideline change at that year. Click to pin the detail panel until you pick another.
Cumulative mortality benefit from optimally-applied GDMT, based on pooled trial analyses. The "4-pillar" regimen delivers an estimated 73% RRR in CV mortality vs. placebo.